Hormone replacement therapy appears to be safe after prophylactic adnexectomy in premenopausal BRCA1/BRCA2 mutation carriers

Jan Lubiński, Henry T. Lynch, Rita Schmutzler, Monique M.A. Brood-Van Zanten, Marius J. Van Der Mooren, René H.M. Verheijen, Peter Kenemans, Tracy Dudding, Judy Kirk, Shirley Hodgson, Lenka Foretova, Barbara Weber, Timothy R. Rebbeck, Jill E. Stopfer, Susan Domchek

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalHereditary Cancer in Clinical Practice
Volume3
Issue number3
StatePublished - Dec 1 2005

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics(clinical)

Cite this

Lubiński, J., Lynch, H. T., Schmutzler, R., Brood-Van Zanten, M. M. A., Van Der Mooren, M. J., Verheijen, R. H. M., Kenemans, P., Dudding, T., Kirk, J., Hodgson, S., Foretova, L., Weber, B., Rebbeck, T. R., Stopfer, J. E., & Domchek, S. (2005). Hormone replacement therapy appears to be safe after prophylactic adnexectomy in premenopausal BRCA1/BRCA2 mutation carriers. Hereditary Cancer in Clinical Practice, 3(3), 87-91.